Literature DB >> 17714761

Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response.

Jérôme Verine1, Nathalie Mourad, Kristell Desseaux, Philippe Vanhille, Laure-Hélène Noël, Hélène Beaufils, Gilles Grateau, Anne Janin, Dominique Droz.   

Abstract

We retrospectively reviewed the clinicopathological features of a series of 68 renal AA amyloidosis observations collected between 1990 and 2005. The amyloidogenic disease was a chronic infection (40.8%), a chronic inflammation (38%), a tumor (9.9%), a hereditary disease (9.9%), or was undetermined in 1.4% of cases. Nephrotic syndrome and renal insufficiency were noted in 63.1% and 75% of patients, respectively. The distribution pattern of glomerular amyloid deposits was mesangial segmental (14.7%), mesangial nodular (26.5%), mesangiocapillary (32.3%), and hilar (26.5%). Glomerular form was observed in 80.9% of cases and vascular form in 19.1%. AA amyloidosis-related inflammation was noted in 30 patients (44.1%) and appeared as a multinucleated giant cell reaction (27.9%) or a glomerular inflammatory infiltrate (25%), including glomerular crescents (17.6%). At the end of follow-up, 26 patients (38.2%) showed end-stage renal disease. The clinical presentation of glomerular and vascular forms was distinct with a clear predominance of proteinuria in glomerular form. Inflammatory reaction was preferentially observed in biopsies with a codeposition of immunoglobulin chains and/or complement factors in AA amyloid deposits. The distribution pattern of glomerular amyloid deposits and glomerular inflammatory reaction were independent factors influencing proteinuria level. Tubular atrophy, abundance, and distribution pattern of glomerular amyloid deposits at the time of biopsy were independent predictors of renal outcome. In conclusion, the glomerular involvement appeared as the determining histological factor for clinical manifestations and outcome of renal AA amyloidosis. AA amyloidosis-related inflammation could partly result from an immune response directed against AA fibrils and could induce amyloid resolution and crescents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714761     DOI: 10.1016/j.humpath.2007.04.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  21 in total

1.  Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Shunsuke Yamada; Akihiro Tsuchimoto; Yoshiki Kaizu; Masatomo Taniguchi; Kosuke Masutani; Hiroshi Tsukamoto; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-29

2.  Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?

Authors:  Ioannis Petrakis; Vasiliki Mavroeidi; Kostas Stylianou; George Efthymiou; Kostas Perakis; Eleftheria Vardaki; Spyridon Stratigis; Kostas Giannakakis; Kostas Kourouniotis; George Amoiridis; Andreas Plaitakis; Maria Joao Saraiva; Ken Ichi Yamamura; Eugene Daphnis
Journal:  Transgenic Res       Date:  2012-07-18       Impact factor: 2.788

Review 3.  Pathology and diagnosis of renal non-AL amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis
Journal:  J Nephrol       Date:  2017-08-21       Impact factor: 3.902

4.  Clinicopathological features of renal amyloidosis: a single-center study on 47 cases.

Authors:  Chang-Qing Luo; Yu-An Zhang; Zhen-Qiong Li; Yu-Mei Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-02-12

5.  Sarcoidosis-associated renal AA amyloidosis and crescentic necrotizing glomerulonephritis.

Authors:  Albert Bui; Cherise Cortese; Nabeel Aslam
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-16

6.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

7.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

8.  Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases.

Authors:  Kemal Kosemehmetoglu; Dilek Ertoy Baydar
Journal:  Int Urol Nephrol       Date:  2012-09-09       Impact factor: 2.370

9.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

10.  Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII.

Authors:  Samih H Nasr; Surendra Dasari; Linda Hasadsri; Jason D Theis; Julie A Vrana; Morie A Gertz; Prasuna Muppa; Michael T Zimmermann; Karen L Grogg; Angela Dispenzieri; Sanjeev Sethi; W Edward Highsmith; Giampaolo Merlini; Nelson Leung; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2016-06-13       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.